Alex

Analyst

representing Sam England)

Analyst

Canaccord Genuity

Analyst

Bank of America

Analyst

on for Patrick Cunningham)

MediaAlpha, Inc. (MAX)

Analyst

Evercore (on behalf of Gavin Clarke)

Equibles does not estimate personal net worth.

About Alex

Alex is recorded as Analyst at representing Sam England), Analyst at Canaccord Genuity, Analyst at Bank of America, Analyst at on for Patrick Cunningham) and Analyst at Evercore (on behalf of Gavin Clarke). Alex has spoken on 2 earnings calls and 2 other investor events across 4 companies, most recently for Okta, Inc. on September 9, 2026. Those appearances were for Okta, Inc. (OKTA), Pinnacle West Capital Corp (PNW), S&P Global Inc. (SPGI) and Vir Biotechnology, Inc. (VIR). MediaAlpha, Inc. is classified in the Internet Content & Information industry within the Communication Services sector. Other companies whose calls Alex spoke on are classified in the Technology, Utilities, Financial Services and Healthcare sectors. Other leadership on record at MediaAlpha, Inc. includes Steven Yi (CEO and Board Member), Patrick R. Thompson (CFO), Patrick Thompson (CFO) and 7 others.

Alex on recent calls

“In the core business, I mean, that's primary what's driving the growth in the future. And you talked about the sales force and the changes you made, how that's working.”

Analyst — representing Sam England), Goldman Sachs Communacopia & Technology Conference · September 9, 2026

“And then just finally on – there was a NUCCA conference yesterday at the commission, and I wasn't able to listen to a lot of it, frankly. But it sounded like there's a lot of kind of excitement in the context of utilities in terms of this resource.”

Analyst — representing Sam England), Pinnacle West Capital Corp Q4 FY2025 Earnings Call · February 25, 2026

“I'm afraid this is a lengthy question, but it's a continuation of what you just talked about, and it's for Sagada and Sally. You talked a lot about the enterprise bundling, licensing, however you want to call it, and vendor consolidation.”

Analyst — representing Sam England), Investor Presentation | S&P Global Investor Day 2025 · November 13, 2025

“First on 5525, So I've apologies if this was already asked, but just on the need for steroid prophylaxis, do you think you'd approach this similarly to studies for your other two assets or maybe a different approach just given the breadth of the EGFR expression?”

Analyst — Bank of America, Vir Biotechnology, Inc. Q4 FY2024 Earnings Call · February 26, 2025